PMV Pharmaceuticals (PMVP) Competitors $1.46 +0.08 (+5.43%) As of 10:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMVP vs. MREO, ABEO, CADL, DBVT, ALLO, EDIT, REPL, LYEL, KYTX, and TKNOShould you be buying PMV Pharmaceuticals stock or one of its competitors? The main competitors of PMV Pharmaceuticals include Mereo BioPharma Group (MREO), Abeona Therapeutics (ABEO), Candel Therapeutics (CADL), DBV Technologies (DBVT), Allogene Therapeutics (ALLO), Editas Medicine (EDIT), Replimune Group (REPL), Lyell Immunopharma (LYEL), Kyverna Therapeutics (KYTX), and Alpha Teknova (TKNO). These companies are all part of the "pharmaceutical products" industry. PMV Pharmaceuticals vs. Its Competitors Mereo BioPharma Group Abeona Therapeutics Candel Therapeutics DBV Technologies Allogene Therapeutics Editas Medicine Replimune Group Lyell Immunopharma Kyverna Therapeutics Alpha Teknova Mereo BioPharma Group (NASDAQ:MREO) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations. Which has more risk and volatility, MREO or PMVP? Mereo BioPharma Group has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, PMV Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Does the media prefer MREO or PMVP? In the previous week, PMV Pharmaceuticals had 2 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 3 mentions for PMV Pharmaceuticals and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 1.70 beat PMV Pharmaceuticals' score of 0.98 indicating that Mereo BioPharma Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mereo BioPharma Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive PMV Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in MREO or PMVP? 62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 5.5% of Mereo BioPharma Group shares are owned by company insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is MREO or PMVP more profitable? PMV Pharmaceuticals' return on equity of -47.94% beat Mereo BioPharma Group's return on equity.Company Net Margins Return on Equity Return on Assets Mereo BioPharma GroupN/A -80.00% -66.94% PMV Pharmaceuticals N/A -47.94%-43.82% Do analysts recommend MREO or PMVP? Mereo BioPharma Group currently has a consensus target price of $7.40, suggesting a potential upside of 303.27%. PMV Pharmaceuticals has a consensus target price of $5.50, suggesting a potential upside of 278.01%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, research analysts clearly believe Mereo BioPharma Group is more favorable than PMV Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20PMV Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, MREO or PMVP? Mereo BioPharma Group has higher revenue and earnings than PMV Pharmaceuticals. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMereo BioPharma Group$10M29.18-$43.25M-$0.07-26.21PMV PharmaceuticalsN/AN/A-$58.71M-$1.57-0.93 SummaryMereo BioPharma Group beats PMV Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get PMV Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMVP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMVP vs. The Competition Export to ExcelMetricPMV PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.63M$2.54B$5.72B$10.39BDividend YieldN/A53.63%5.53%4.58%P/E Ratio-0.9323.3076.1626.62Price / SalesN/A519.56471.8492.08Price / CashN/A171.0137.4661.85Price / Book0.435.3813.336.46Net Income-$58.71M$32.95M$3.29B$271.49M7 Day Performance16.40%3.62%2.29%2.97%1 Month Performance-1.69%5.55%4.44%7.56%1 Year Performance-2.35%1.48%75.18%30.09% PMV Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMVPPMV Pharmaceuticals3.1052 of 5 stars$1.46+5.4%$5.50+278.0%-7.4%$77.63MN/A-0.9350News CoverageAnalyst RevisionGap UpMREOMereo BioPharma Group2.1696 of 5 stars$1.85+6.3%$7.40+300.0%-56.0%$276.66M$10M-26.4340Positive NewsABEOAbeona Therapeutics4.0256 of 5 stars$5.48+1.9%$19.50+255.8%-6.0%$275.88M$3.50M7.8390Positive NewsCADLCandel Therapeutics2.7064 of 5 stars$5.23+8.7%$20.00+282.4%-23.8%$264.05M$120K-7.5860Positive NewsDBVTDBV Technologies2.8112 of 5 stars$9.50flat$14.75+55.3%+167.1%$260.25M$4.15M-1.9980ALLOAllogene Therapeutics3.1283 of 5 stars$1.17+0.9%$8.44+621.7%-56.2%$257.38M$20K-1.05310Positive NewsEDITEditas Medicine3.8698 of 5 stars$3.00+6.0%$5.10+70.0%-17.8%$254.47M$32.31M-1.05230REPLReplimune Group4.5121 of 5 stars$3.27+1.6%$6.50+98.8%-60.5%$251.73MN/A-1.01210Gap DownLYELLyell Immunopharma1.7101 of 5 stars$13.17+0.6%$15.00+13.9%-53.9%$251.48M$60K-0.54270High Trading VolumeKYTXKyverna Therapeutics2.351 of 5 stars$6.52+12.4%$16.60+154.6%+8.0%$250.82M$7.03M-1.7796News CoverageHigh Trading VolumeTKNOAlpha Teknova2.0188 of 5 stars$5.32+14.7%$10.00+88.0%+5.5%$248.31M$37.74M-12.67240High Trading Volume Related Companies and Tools Related Companies Mereo BioPharma Group Alternatives Abeona Therapeutics Alternatives Candel Therapeutics Alternatives DBV Technologies Alternatives Allogene Therapeutics Alternatives Editas Medicine Alternatives Replimune Group Alternatives Lyell Immunopharma Alternatives Kyverna Therapeutics Alternatives Alpha Teknova Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMVP) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMV Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PMVP Stock Alerts